HAE focus is stronger, but risk is concentrated
- ORLADEYO is the core business, with Q1 2026 net revenue of $148.3 million.
- The Astria deal added navenibart, a long-acting injectable HAE drug candidate.
- Management says navenibart trial enrollment is on track to finish by the end of June 2026.
- A $697.8 million non-cash IPR&D charge made GAAP losses look much worse in Q1.
- The main worry is that BioCryst is now more tied to one disease market and one patent fight.
A sharper HAE bet
BioCryst has become a focused HAE company. HAE, or hereditary angioedema, is a rare disease that can cause sudden swelling attacks. ORLADEYO, its once-daily oral drug, is already commercial and produced $148.3 million of net revenue in Q1 2026.
The bull case is simple. ORLADEYO keeps growing, navenibart gives BioCryst a long-acting injectable option, and the company can offer patients two different ways to prevent HAE attacks. Management also plans to wind down internal discovery work and spend more energy on late-stage assets and outside deals, which could make capital use tighter.
The bear case is also clear. BioCryst is more concentrated in HAE after buying Astria. It also took on a new $400 million term loan tied to that deal. If ORLADEYO slows, navenibart disappoints, or the ORLADEYO patent litigation goes badly, the stock has fewer places to hide.
The next proof points are watchable. Investors need to see navenibart enrollment complete, the pediatric ORLADEYO manufacturing issue fixed, ORLADEYO track toward 2026 guidance of $625 million to $645 million, and progress on the Annora patent case.
One commercial engine funds the buildout
BioCryst makes money mainly by selling ORLADEYO. After selling its European ORLADEYO business in 2025, the company is more focused on the U.S. market, which management has said should be about 80 percent of peak global revenue.
The Astria acquisition changed the story. BioCryst is no longer only an oral ORLADEYO story. It now owns navenibart, a long-acting injectable plasma kallikrein inhibitor for HAE, and wants to build a broader HAE franchise.
Partners may help fund the plan. In May 2026, BioCryst licensed European rights to navenibart to Neopharmed for $70.0 million upfront, with up to $275.0 million in future regulatory and sales milestones plus tiered royalties.
This model breaks if ORLADEYO cash flow is not enough to support debt, trials, and launches. It also breaks if the company cannot integrate Astria or if the new pediatric ORLADEYO formulation stays delayed because of manufacturing.
Oral now, injectable next
ORLADEYO
ORLADEYO is a once-daily oral drug used to prevent HAE attacks. It is the main revenue source and generated $148.3 million of net revenue in Q1 2026.
Pediatric ORLADEYO granules
This oral granule version was approved for children ages 2 to 11 in December 2025. Prescriptions have started, but fulfillment is delayed by a manufacturing issue.
Navenibart
Navenibart is a long-acting injectable HAE prevention candidate acquired with Astria. The ALPHA-ORBIT pivotal trial was expected to complete enrollment by the end of June 2026 with about 145 patients.
BCX17725
BCX17725 is in Phase 1 testing for Netherton Syndrome, a rare skin disease. BioCryst expects data from patient cohorts by the end of 2026.
STAR-0310
STAR-0310 is a monoclonal antibody for atopic dermatitis that came from Astria. BioCryst plans to seek strategic alternatives for this asset rather than fund it alone.
Internal discovery programs
BioCryst is winding down internal discovery and closing its Birmingham research work to focus on external innovation and later-stage assets. That may save money, but the exact cost and timeline remain open questions.
Revenue is still mostly ORLADEYO
BioCryst reports one operating segment, rare-disease drug development and commercialization. For Q1 2026 revenue mix, ORLADEYO product revenue was $148.3 million of total revenue of $156.4 million, with the rest mainly license and other revenue.
What could break the thesis
ORLADEYO patent loss
High impact · Medium oddsAnnora filed a Paragraph IV challenge seeking approval for a generic ORLADEYO before four Orange Book patents expire in 2039. BioCryst sued in Delaware. A bad outcome could open the door to earlier generic competition in the U.S.
Navenibart trial or integration stumble
High impact · Medium oddsThe Astria acquisition is meant to turn BioCryst into a dual oral and injectable HAE company. That only works if navenibart advances cleanly and BioCryst manages the combined portfolio well. Any delay after enrollment would weaken the HAE franchise plan.
Debt limits flexibility
Medium impact · Medium oddsBioCryst added a new $400 million Blackstone term loan to help finance Astria. The loan is secured by substantially all company assets and comes with covenants. That raises pressure on ORLADEYO cash flow and may limit choices if trials or launches slip.
Pediatric launch delay lasts too long
Medium impact · Medium oddsThe FDA approved pediatric ORLADEYO granules for children ages 2 to 11, but management disclosed a fulfillment delay tied to manufacturing. The issue is not related to capsule supply, but it could still slow uptake in a key growth area.
HAE market competition
Medium impact · High oddsBioCryst now has more ways to compete in HAE, but rivals also have approved and pipeline drugs. The company must prove patients and doctors want both ORLADEYO and navenibart. If competitors win share or price pressure rises, the franchise could grow slower than planned.
In one breath
What does BioCryst Pharmaceuticals do?
BioCryst develops and sells rare-disease drugs. Its main product is ORLADEYO, an oral medicine used to prevent HAE attacks.
Why did BioCryst buy Astria Therapeutics?
Astria added navenibart, a long-acting injectable HAE drug candidate. BioCryst wants to offer both an oral and injectable option for HAE prevention.
Why did BioCryst report such a large Q1 loss?
The Q1 2026 GAAP net loss was mainly driven by a one-time, non-cash $697.8 million charge for acquired in-process research and development from the Astria deal. That accounting charge does not mean the core ORLADEYO business suddenly collapsed.
What should investors watch next for BCRX?
The key items are navenibart trial progress, pediatric ORLADEYO supply, ORLADEYO revenue versus 2026 guidance, and the Annora patent litigation. Those events will show whether the HAE franchise plan is working.